Literature DB >> 17707957

Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.

Mehmet Ceyhan1, Inci Yildirim, Paul Balmer, Christine Riley, Gouri Laher, Nick Andrews, Ray Borrow, Nese Kurt, Mehmet Turgut, Aysel Aydogan, Cigdem Ecevit, Gulnar Uysal, Viola Schultze.   

Abstract

Like many other developing countries; there is no accurate information about the antibody levels against Neisseria meningitidis in Turkey. We collected serum samples from four health centers located in different geographic regions and stratified according to age in order to obtain a baseline seroprevalence of protective antibodies to meningococcal serogroup C and provide data on seroprevalence of IgG antibodies to serogroups A, C, W135 and Y. Sera were tested for serum bactericidal antibodies (SBA) to serogroup C meningococci using rabbit serum as the complement source and by a bead based assay for serogroup A, C, W135 and Y-specific IgG. It was observed that 30% and 12% of individuals within the study population had SBA titers of > or =8 and > or =128, respectively. Overall; at least 70% of the population are susceptible (SBA titer <8) to meningococcal serogroup C disease. The rate of susceptibility was highest in infants aged 7-12 months and young children (1-4 years). Regardless of age, for serogroup A, C, W135 and Y, 60.5%, 27.2%, 12.3% and 19.2% of subjects, respectively, had serogroup-specific IgG concentrations > or =2 microg/mL. These data highlight that a large proportion of the Turkish population are susceptible to serogroups C, W135 and Y and should be considered, along with serogroup-specific disease incidence data, in future decisions on possible meningococcal vaccination programmes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707957     DOI: 10.1016/j.vaccine.2007.07.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.

Authors:  Christopher J Gill; Roger Baxter; Alessandra Anemona; Giuseppe Ciavarro; Peter Dull
Journal:  Hum Vaccin       Date:  2010-11-01

2.  Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Authors:  George K Siberry; Paige L Williams; Jorge Lujan-Zilbermann; Meredith G Warshaw; Stephen A Spector; Michael D Decker; Barbara E Heckman; Emily F Demske; Jennifer S Read; Patrick Jean-Philippe; William Kabat; Sharon Nachman
Journal:  Pediatr Infect Dis J       Date:  2010-05       Impact factor: 2.129

3.  Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk?

Authors:  Richarda M de Voer; Fiona R M van der Klis; Laetitia E M Niers; Ger T Rijkers; Guy A M Berbers
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

4.  Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.

Authors:  Richarda M de Voer; Liesbeth Mollema; Rutger M Schepp; Sabine C de Greeff; Pieter G M van Gageldonk; Hester E de Melker; Elisabeth A M Sanders; Guy A M Berbers; Fiona R M van der Klis
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

5.  Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.

Authors:  Markus Knuf; Yaela Baine; Veronique Bianco; Dominique Boutriau; Jacqueline M Miller
Journal:  Hum Vaccin Immunother       Date:  2012-04-09       Impact factor: 3.452

6.  A Survey of Serum Bactericidal Antibodies against Neisseria meningitidis Serogroups A, C, W and Y in Adolescents and Adults in the Republic of Korea.

Authors:  Jin-Han Kang; Yan Miao; SooYoung Lee; Jong-Hyun Kim; Kyung-Yil Lee; Sang Hyuk Ma; Dae Sun Jo; HyoYoung Song; Mendel Haag
Journal:  Infect Chemother       Date:  2016-03-31

7.  Different Long-Term Duration of Seroprotection against Neisseria meningitidis in Adolescents and Middle-Aged Adults after a Single Meningococcal ACWY Conjugate Vaccination in The Netherlands.

Authors:  Milou Ohm; Debbie M van Rooijen; Axel A Bonačić Marinović; Mariëtte B van Ravenhorst; Marieke van der Heiden; Anne-Marie Buisman; Elisabeth A M Sanders; Guy A M Berbers
Journal:  Vaccines (Basel)       Date:  2020-10-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.